

Now recruiting for clinical studies of canine bladder cancer



About the studies

NC State College of Veterinary Medicine is recruiting for studies of canine bladder cancer (urothelial carcinoma/transitional cell carcinoma, UC/TCC).



Goals

These studies will investigate:

1. Whether urine-based screening for a genetic marker (a specific mutation in the *BRAF* gene) can detect UC/TCC in dogs before the onset of clinical signs.
2. Whether a dietary supplement delays the onset of clinical signs in dogs that have a detectable urinary *BRAF* mutation, but which have no existing clinical signs of UC/TCC.
3. Whether the same dietary supplement slows progression of the disease in dogs recently diagnosed with UC/TCC, when provided in combination with standard of care treatment.

Is my dog eligible?

Complete this online survey to find out

<https://redcap.link/NCStateUCStudyQ1>

Questions? Contact us at:

UCClinicalTrials@ncsu.edu



Eligibility criteria

To be eligible for enrollment, a dog must either:

a. Have been diagnosed with UC/TCC within the past six weeks, and have not begun chemotherapy.

OR:

b. Be aged six years or older, with no obvious signs of UC/TCC (such as straining to urinate, blood in the urine), from one of the following breeds:

American Eskimo Dog, Beagle, Russell Terrier, Parson Russell Terrier, Scottish Terrier, Shetland Sheepdog, West Highland White Terrier.

Additionally, owners must be committed to bringing their dog for regular evaluation at NC State College of Veterinary Medicine (typically every 1-3 months for up to 12 months), and completing a series of study questionnaires.



Study benefits - provided to you at **NO COST**

- **Monthly *BRAF* mutation testing** of your dog's urine
- **Clinical evaluation** for the presence of UC/TCC
- **Standard of care treatment** (for dogs with detectable UC/TCC) - *treatment selection will be based on clinician's recommendations in consultation with the owner, generally mitoxantrone chemotherapy +/- an NSAID, or an NSAID alone*
- **Dietary supplement or placebo** (*once-daily tablet*)
- **Periodic re-evaluation** by ultrasound